drugset
drugset / Trial / NCT01325311

Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer

NCT01325311 ↗

Phase 2 Completed 15 enrolled National Cancer Institute (NCI)
RandomizedParallel-groupDouble-blindTreatment

Summary

This randomized phase II trial studies cholecalciferol and genistein compared to placebo in treating patients with early stage prostate cancer. Cholecalciferol and genistein may slow the growth of cancer cells and may be an effective treatment for prostate cancer.

Timeline

Start
2011-12
Primary completion
2014-07
Completion
2014-07

Outcome

Missed primary endpoint

registry analysis (superiority or other test); Arm II (Placebo) vs Arm I (Cholecalciferol, Genistein); p = 0.922; t-test, 2 sided NCT01325311 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Cholecalciferol Other / unclassified 200000 iu Oral
Subject Genistein Other / unclassified 600 mg Oral

Indications

prostate adenocarcinoma